Skip to search formSkip to main contentSkip to account menu

Selective Estrogen Receptor Degrader/Modulator RAD1901

Known as: RAD1901, SERD/SERM RAD1901 
An orally available, selective estrogen receptor degrader (SERD) and selective estrogen receptor modulator (SERM), with potential antineoplastic and… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
e15647Background: Antiestrogens are a mainstay of treatment for estrogen receptor positive (ER+) breast cancer in both the… 
2018
2018
Background: Breast cancer is subdivided into categories based on tumor receptor status, with estrogen-receptor positive (ER… 
2018
2018
Background: Targeting estrogen receptor (ER) signalling is the main therapeutic option for ER+ breast cancer (BC). However, over… 
2017
2017
Objective: The aim of the study was to assess the efficacy and safety of RAD1901, an oral estrogen receptor ligand, for the… 
2016
2016
TPS627Background: RAD1901 is a novel, orally available selective estrogen receptor degrader (SERD) that binds to both mutant and… 
2016
2016
Estrogen and the estrogen receptor (ER) are known to be prominent drivers of breast tumourigenesis and breast cancer progression… 
2016
2016
The current NCCN treatment guidelines for ER+ breast cancer involves the use of approved agents such as fulvestrant, tamoxifen… 
2016
2016
Despite advances in the treatment of metastatic breast cancer, many women eventually relapse with more aggressive forms of… 
2015
2015
TPS638 Background: RAD1901 is a novel, non-steroidal, orally bioavailable selective estrogen receptor degrader (SERD…